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SUMMARY
The transition of ductal carcinoma in situ (DCIS) to invasive carcinoma is a poorly understood key event in
breast tumor progression. Here, we analyzed the role of myoepithelial cells and fibroblasts in the progression
of in situ carcinomas using a model of human DCIS and primary breast tumors. Progression to invasion was
promoted by fibroblasts and inhibited by normal myoepithelial cells. Molecular profiles of isolated luminal
epithelial and myoepithelial cells identified an intricate interaction network involving TGFb, Hedgehog, cell
adhesion, and p63 required for myoepithelial cell differentiation, the elimination of which resulted in loss of
myoepithelial cells and progression to invasion.INTRODUCTION
The natural history of breast cancer involves progression
through clinical and pathologic stages starting with abnormal
epithelial proliferation, progressing into in situ and invasive carci-
nomas, and culminating in metastatic disease (Burstein et al.,
2004). DCIS is thought to be a precursor of invasive ductal car-
cinoma based on molecular, epidemiological, and pathological
studies (Burstein et al., 2004). Surgical margins and histologic
features have been associated with increased risk of subsequent
tumor events, but none of these predicted the risk of invasive re-
currence (Fisher et al., 1999; Gauthier et al., 2007). Comprehen-
sive molecular profiling studies comparing DCIS and invasive394 Cancer Cell 13, 394–406, May 2008 ª2008 Elsevier Inc.ductal carcinomas have failed to identify tumor-stage-specific
signatures (Chin et al., 2004; Ma et al., 2003; Porter et al.,
2003; Yao et al., 2006). However, these studies have focused
mainly on the tumor epithelial cells, and the role of the microen-
vironment in tumor progression has not been explored.
Epithelial-mesenchymal interactions are important for normal
mammary gland development and for breast tumorigenesis
(Howlett and Bissell, 1993). In vivo and in vitro studies have dem-
onstrated that ECM (extracellular matrix) molecules and cells
composing the microenvironment modulate tissue-specificity
of the normal breast as well as the growth, survival, polarity,
and invasive behavior of breast cancer cells (Bissell et al.,
2005; Weinberg and Mihich, 2006). In the normal mammarySIGNIFICANCE
Although there has been a dramatic improvement in our ability to detect DCIS, our understanding of the factors involved in
its progression has just begun. Analysis of epithelial cells fromDCIS and invasive tumors has failed to identify stage-specific
differences. However, themyoepithelial cell layer and basementmembrane, present only in DCIS, are key distinguishing and
diagnostic features. Here, we show that a key event of tumor progression is the disappearance of themyoepithelial cell layer
due to defective myoepithelial cell differentiation regulated by intrinsic andmicroenvironmental signals. Thus, myoepithelial
cells can be considered gatekeepers of the in situ to invasive carcinoma transition; understanding the pathways that reg-
ulate their differentiation may open new venues for cancer therapy and prevention.
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Myoepithelial Control of Breast Tumor Progressiongland, a layer of myoepithelial cells that produces and is in con-
tact with the basement membrane surrounds luminal epithelial
cells, which in turn line the ducts and the alveoli. In addition to
playing a role in expelling milk from the ducts during lactation
via their contractile function, myoepithelial cells increasingly
are recognized as important regulators of normal mammary
gland development and function due to their effect on luminal
epithelial cell polarity, branching, and differentiation (Bissell
et al., 2005). Myoepithelial cells also have been labeled ‘‘natural
tumor suppressors’’ due to their negative effects on tumor cell
growth, invasion, and angiogenesis achieved via secretion of
protease inhibitors and downregulation of MMP (matrix metallo-
protease) levels (Barsky and Karlin, 2005; Polyak and Hu, 2005).
These conclusions have been largely based on coculture assays;
the role of myoepithelial cells in tumorigenesis and the basis of
their disappearance during invasive progression have not been
explored. The tumor-suppressive function of myoepithelial cells
progressively gets lost during the in situ to invasive carcinoma
transition. Indeed, the diagnostic criterion that distinguishes
invasive from in situ carcinomas is the disappearance of the
organized myoepithelial cell layer and the basement membrane
(Lerwill, 2004).
To explore the involvement of the microenvironment in tumor
progression, we previously analyzed the gene expression and
DNA methylation profiles of different cell types from normal
breast tissue, DCIS, and invasive breast carcinomas and
observed dramatic changes in all cell types during tumor pro-
gression (Allinen et al., 2004; Hu et al., 2005). Importantly, myo-
epithelial cells associated with DCIS were not phenotypically
normal; they had lost some of their differentiation markers and
had upregulated genes promoting angiogenesis and invasion.
While the physiological relevance of these molecular changes
was unknown, based on our data we hypothesized that abnor-
mal DCIS-associated myoepithelial cells, together with different
stromal cells, degrade the basement membrane resulting in the
progression of in situ carcinomas to invasive tumors. Testing
this hypothesis required an experimental model of DCIS that
faithfully reproduced human disease, since analysis of human
tissue allows only correlative studies. The MCF10A series is
one of the few human models of breast tumor progression (Miller,
2000), although it is likely to reflect only a subset of breast tumors
with basal-like features. A derivative of MCF10A cells is the
MCF10ADCIS.com cell line (subsequently referred to as
MCFDCIS) (Miller et al., 2000), which reproducibly forms com-
edo DCIS-like lesions that spontaneously progress to invasive
tumors. This MCFDCIS xenograft model highly resembles
human disease with respect to histopathology and natural his-
tory. Furthermore, we here show that the gene expression pro-
files of epithelial and myoepithelial cells purified from MCFDCIS
xenografts are also highly similar to those from primary human
DCIS tumors. We used this model to explore the relative impor-
tance of myoepithelial cells and stromal fibroblasts in the in situ
to invasive breast carcinoma transition. In this study, we demon-
strated that normal myoepithelial cells suppress, but fibroblasts
enhance, tumor growth and invasive progression in the absence
of detectable genomic alterations in the tumor epithelial cells.
We identified an intricate network involving TGFb, Hedgehog
(Hh), cell adhesion, and p63 that appears to play an essential
role in myoepithelial cell differentiation, as elimination of keymediators of these pathways led to the loss of myoepithelial cells
and progression to invasion. The gene expression profiles of
epithelial and myoepithelial cells from primary human breast
tissue correlated with these findings and supported the hypoth-
esis that in situ to invasive carcinoma transition is regulated by
loss of normal myoepithelial cell function.
RESULTS
Characterization of the MCFDCIS Cells
and Their Xenografts
To explore whether MCFDCIS provided a good model for pri-
mary human DCIS, xenografts were analyzed for histology and
molecular markers. We chose subcutaneous instead of ortho-
topic injections because the progression and phenotype of the
tumors were different in the mammary fat pad presumably due
to the local microenvironment (Figures S1A and S1B). Subcuta-
neous xenografts were similar to human high-grade comedo
DCIS. The duct-like structures were surrounded by basement
membrane positive for laminin 5 and contained a layer of cells
positive for myoepithelial markers (smooth muscle actin-SMA,
CD10, and p63) (Figure 1A). Analysis of the tumors at different
time points (3–8 weeks) after injection revealed a progression
from DCIS to invasive histology (Figure 1B). In DCIS, both SMA
and p63 were expressed in the myoepithelial cell layer, whereas
in invasive tumors, SMA-positive cells were stromal myofibro-
blasts, and a subset of tumor epithelial cells was p63 positive.
We tested several other human breast cancer cell lines in
xenograft assays; however, none of these formed tumors with
DCIS histology (Figure S1C). We reasoned that the unique
characteristic of MCFDCIS cells may be due to their proposed
bipotential progenitor properties (Santner et al., 2001). To inves-
tigate this, we performed immunofluorescence in situ hybridiza-
tion (iFISH) analysis of MCFDCIS xenografts to test whether both
epithelial and myoepithelial cells were derived from MCFDCIS
cells and if the myoepithelial cell layer disappeared as tumors
became invasive. Samples collected at different time points after
injection were hybridized with fluorescently labeled human
and mouse cot-1 DNA as probes for FISH and stained with
pancytokeratin (panCK) and SMA antibodies for epithelial and
myoepithelial cells, respectively. As anticipated, panCK+ tumor
epithelial cells were indeed of human origin in all tumors
(Figure S2A). SMA+ myoepithelial cells were also of human origin
(Figure 1C), confirming that MCFDCIS cells are bipotential pro-
genitors. In contrast, SMA+ myofibroblasts in the stroma were
of murine origin in all xenografts. iFISH analysis also revealed
the gradual disappearance of SMA+ myoepithelial cells coincid-
ing with the progression of DCIS to invasive tumors (Figure 1C).
Since other MCF10A derivatives were also proposed to be pro-
genitors (Santner et al., 2001), we tested these in xenograft
assays as well, but they were either nontumorigenic (MCF10AT
cells) or formed invasive tumors (MCF10CA cells) (data not
shown). Thus, of all the cells tested, the MCFDCIS cell line was
the only human breast cancer cell line that formed DCIS xeno-
grafts in our hands.
To dissect the progenitor properties of MCFDCIS cells, we
analyzed the expression of known basal/progenitor and differen-
tiated luminal and myoepithelial cell markers (Table S1) in cul-
tured cells and xenografts. Immunohistochemistry and FACSCancer Cell 13, 394–406, May 2008 ª2008 Elsevier Inc. 395
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Myoepithelial Control of Breast Tumor ProgressionFigure 1. Properties of MCFDCIS Cells and Derived Xenografts
(A) Comparison of MCFDCIS xenografts and human high-grade comedo DCIS analyzed by hematoxylin-eosin staining (H&E) to depict histology and immuno-
histochemistry for the expression of SMA, CD10, p63, ITGB6, and laminin 5.
(B) Progression of the MCFDCIS xenografts. Histology of the tumors (H&E) and expression of SMA, p63, and ITGB6 were analyzed at the indicated time points
after injection.
(C) iFISH analysis of a time course experiment. Immunofluorescence using SMA antibody (blue) identifies myoepithelial cells or myofibroblasts. Fluorescently
labeled human (green) and mouse (red) Cot1 DNA were used as probes for FISH. Yellow arrows and stars indicate human myoepithelial cells and mouse
myofibroblasts, respectively.
(D and E) Single (D) and dual (E) immunohistochemical analyses of the indicated markers in MCFDCIS cells (in vitro) or xenografts (in vivo). Insets show
colocalization of the indicated markers in a single cell and the mutually exclusive expression of p63 and MUC1 in xenografts.
Scale bars correspond to 100 mm in all panels.analyses showed that MCFDCIS cells in 2D culture were
uniformly positive for panCK, CK18, ESA, CDH1, CD44, CK17,
CK5/6, p63, VIM, ITGA6, and ITGB6; partially positive for
MUC1 and CK14; and negative for CD24, SMA, CK19, and
CD10 (Figure 1D and Figure S2B). In xenografts, most tumor ep-
ithelial cells were positive for panCK, ESA, CD44, CK17, CDH1,
and VIM. In DCIS, p63 and SMA expression was limited to the
myoepithelial cells that also showed decreased or no expression
of MUC1, CD24, and CK18, while CK5/6 and CK14 demon-
strated heterogeneous staining patterns with all cells positive
in some areas and only the myoepithelial cells positive in others
(Figure 1D). Doublestaining confirmed the colocalization of mul-
tiple markers characteristic of a particular cellular phenotype
within one cell and the mutually exclusive expression of p63
and MUC1 in xenografts following differentiation (Figure 1E).
Thus, based on our analyses, in culture, MCFDCIS cells had
progenitor characteristics, and in xenografts, they differentiated
into luminal and myoepithelial cells.
To determine if all or only a subpopulation of MCFDCIS cells had
progenitor properties, we sorted the cells into MUC1+ and
MUC1 fractions and injected them into mice (Figure S2C).
MUC1 expressionhasbeenused for identification ofcells withpro-
genitor properties (Gudjonsson et al., 2002b; Stingl et al., 2005),396 Cancer Cell 13, 394–406, May 2008 ª2008 Elsevier Inc.and this was the only cell surface marker that we found heteroge-
neously expressed in MCFDCIS cells in culture. Both MUC1+ and
MUC1 cells gave rise to DCIS tumors (Figure S2C), suggesting
that both populations have bipotential progenitor properties. We
also derived single-cell clones of MCFDCIS cells with different
CK14 and MUC1 expression levels (Figures S2D and S2E). Four
of these independent clones were injected into mice and resulting
xenografts from all four had DCIS histology and showed the same
CK14, MUC1, SMA, and p63 expression patterns (Figure S2F).
Thus, using this approach, we found that all or a significant fraction
of MCFDCIS cells may have bipotential progenitor properties, and
the expression patterns of some luminal (MUC1 and CD24) and
myoepithelial (CK14, p63, and SMA) markers were discordant in
2D culture and in xenografts, suggesting that differentiation only
occurs in vivo.
Similarity of the MCFDCIS Model to Human DCIS
To ensure that results obtained using this model are relevant to
human disease, it was essential to establish if the MCFDCIS xe-
nografts reproduce human breast tumors. To compare genetic
alterations in cells from the MCF10A-series and MCFDCIS-
derived xenografts to those found in primary human breast tu-
mors, we performed SNP (single nucleotide polymorphism) array
Cancer Cell
Myoepithelial Control of Breast Tumor ProgressionFigure 2. Similarity of the MCFDCIS Model to Human DCIS
(A) Semiquantitative RT-PCR analysis of the expression of the indicated genes in MUC1+ and ITGB6+ cells purified from DCIS xenografts.
(B) Immunofluorescence analysis of CK5 (orange) and p53 (green) expression in human DCIS. Red arrows mark double-positive abnormal myoepithelial cells in
the basal layer, whereas yellow and white arrows mark CK5+ normal myoepithelial and p53+ tumor epithelial cells, respectively. Scale bar corresponds to 50 mm.
(C) Dendogram depicting cluster analysis of SAGE libraries to delineate similarities of MUC1+ and ITGB6+ cells to human breast epithelial and myoepithelial cells,
respectively.
(D) Gene ontology categories enriched in ITGB6+ and MUC1+ cells from MCFDCIS xenografts and epithelial and myoepithelial cells from primary human breast
tissue. Scores > 1.3 correspond to p < 0.05.
(E) qPCR analysis of MMP14 in bulk DCIS and invasive ductal carcinoma (IDC) and in epithelial and myoepithelial cells, and myofibroblasts from normal human
breast tissue, in situ carcinomas, and invasive carcinomas.
(F) qPCR analysis of MMP14 in MUC1+ and ITGB6+ cells.analyses. All MCF10A-derived cells had copy number gain at
chromosome 8q24 and homozygous deletion of CDKN2A (Fig-
ures S3A and S3B). Both of these genetic alterations are known
to occur in human breast carcinomas (Cairns et al., 1995; Yokota
et al., 1999), supporting the similarity between the MCFDCIS
model and human disease.
To define the similarity of MCFDCIS xenografts to human
DCIS at the cellular level, we purified luminal and myoepithelial
cells using MUC1 and integrin b6 (ITGB6) as cell surface
markers, respectively. ITGB6 has been identified as a gene
upregulated by p63 (Carroll et al., 2006) and TGFb1 (Zambruno
et al., 1995). In MCFDCIS-derived DCIS xenografts and in hu-
man DCIS, ITGB6 was specifically expressed in myoepithelial
cells (Figure 1A), making it an ideal cell surface marker for their
purification. The purity of the MUC1+ and ITGB6+ cells was
confirmed by semiquantitative RT-PCR analysis of cell type-
specific markers. Myoepithelial cell markers CD10 (MME),
SMA (ACTA2), and p63 (TP63) were present only in ITGB6+
cells (Figure 2A), consistent with their myoepithelial phenotype.
Although the cells were separated based on MUC1 and ITGB6
cell-surface markers, the expression of MUC1 and ITGB6mRNAs were not completely mutually exclusive in the two
cell populations.
SNP array analysis of the isolated cells confirmed that both
MUC1+ and ITGB6+ cells are genetically abnormal and have
the same copy number changes as parental MCFDCIS cells (Fig-
ures S3D and S3E). Our previous study in human tumors found
that DCIS-associated myoepithelial cells do not have clonal
somatic copy number alterations (Allinen et al., 2004). This
seeming discrepancy could be due to the fact that MCFDCIS
cells are bipotential tumor-initiating cells, whereas the majority
of myoepithelial cells in DCIS represent cells of normal ducts/al-
veoli into which tumors spread (Figure S4). A prediction of this
hypothesis is that in basal-like DCIS (which the MCFDCIS model
represents) rare genetically abnormal myoepithelial cells can be
found in the area of tumor initiation. To test this hypothesis, we
performed combined immunofluorescence staining for p53,
a gene frequently mutated and overexpressed in basal-like
tumors, and CK5, a myoepithelial cell marker, on human basal-
like DCIS. As depicted in Figure 2B, we observed occasional
p53+/CK5+ cells in the basal layer of some human DCIS poten-
tially identifying genetically abnormal bipotential progenitorsCancer Cell 13, 394–406, May 2008 ª2008 Elsevier Inc. 397
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CK5+/p53+ positive cells in 8% of cases and enrichment in
basal-like tumors. These findings strengthen the similarity of
the MCFDCIS model to human basal-like DCIS and imply that
findings obtained in this model are likely to be relevant to human
disease.
Next we analyzed the comprehensive gene expression pro-
files of MUC1+ and ITGB6+ cells using SAGE. SAGE data further
supported the myoepithelial and luminal characteristics of
ITGB6+ and MUC1+ cells, respectively, since several known
markers of these cell types were almost mutually exclusively ex-
pressed in the respective SAGE libraries (Table 1 and Table S5).
Furthermore, genes differentially expressed between ITGB6+
and MUC1+ cells were also differentially expressed between
myoepithelial and epithelial cells from human breast tissue
(Table 1 and Table S5). Hierarchical cluster analysis of SAGE
libraries also demonstrated the myoepithelial and luminal fea-
tures of ITGB6+ and MUC1+ cells, respectively (Figure 2C).
Functional Analysis of Cell Type-Specific Gene
Expression Patterns
Functional annotation of the genes differentially expressed be-
tween ITGB6+ and MUC1+ cells from xenografts and between
myoepithelial and epithelial cells from human breast tissue re-
vealed statistically significant enrichment of genes involved in
ECM and basement membrane and development in ITGB6+
and myoepithelial cells (Figure 2D). The functional similarity be-
tween MUC1+ and epithelial cells was more limited, reflecting
the higher diversity of luminal cells. We also performed network
analysis of SAGE data using MetaCore as previously described
(Shipitsin et al., 2007). These analyses strongly suggested that
myoepithelial and ITGB6+ cells from human breast tissue and
xenografts, respectively, have very similar phenotypes likely reg-
ulated by TGFb and VEGFA, and their main functions involve
ECM, cytoskeleton, and membrane remodeling and lipoprotein
metabolism (Figure S5). Importantly, genes overexpressed in
myoepithelial cells were also overexpressed in ITGB6+ cells
and vice versa (Table S3). Both pair-wise comparisons
(ITGB6+/MUC1+ and myoepithelial/epithelial cells) showed re-
markably close enrichment pattern in GO processes, canonical
pathway maps, and disease biomarkers, which is highly nonran-
dom, as MetaCore contains 600 pathway maps, over 2000 GO
processes, and >500 disease categories. Common maps in-
cluded cell adhesion, ECM remodeling, keratin filaments, TGFb
and Wnt signaling, and niacin/HDL metabolism; common GO
processes included cell adhesion and actin cytoskeleton reorga-
nization, whereas the most affected disease biomarkers in-
cluded breast, endocrine gland, and urogenital neoplasms,
and epithelial carcinoma (Table S4).
Both the TGFb1 and Hh signaling pathways have been impli-
cated in the regulation of progenitor cell function and myoepithe-
lial differentiation, and SAGE and pathway analyses indicated
their activation in ITGB6+ and in human myoepithelial cells
(Figure S5; Table 1; Table S3). To dissect the possible mecha-
nism of their cell type-specific activation, we analyzed the
expression of their signaling components by semiquantitative
RT-PCR in MUC1+ and ITGB6+ cells. TGFBR1 and TGFBR2
(receptors for TGFb1) and PTCH1, PTCH2, and SMO (receptors
for Hh) were equally present in both cell types, whereas SMAD2,398 Cancer Cell 13, 394–406, May 2008 ª2008 Elsevier Inc.SMAD3, and GLI2 (transcription factors); IHH (a ligand for
PTCH); and TGFb1 transcriptional targets SMAD7 and TGFBI
were expressed more abundantly in ITGB6+ cells (Figure 2A).
These data suggest that specific activation of TGFb1 targets
in ITGB6+ cells may be due to the restricted expression of
SMAD2 and SMAD3 in these cells, a finding that was confirmed
also by immunohistochemical analysis (data not shown). Hh
signaling and GLI2 expression may be upregulated in ITGB6+
cells due to the high expression of IHH (Figure 2A) and BGN
(Table 1).
The Importance of the Basement Membrane
in Progression to Invasion
The gene expression profiles of ITGB6+ and myoepithelial cells
from primary human breast tissue suggested that one of their
main functions is the synthesis and maintenance of the base-
ment membrane (BM). BM degradation is a hallmark of ma-
lignancy and the definition of invasive progression, yet the under-
lying molecular mechanism is undefined. Several MMPs have
been implicated to play a role in this process, but a recent study
suggested that MMP14, MMP15, and MMP16 are the most likely
to degrade BM in vivo (Hotary et al., 2006). To determine the
expression pattern of these three MMPs in breast tumor progres-
sion, we analyzed our SAGE data on multiple cell types isolated
from normal and neoplastic breast tissue (Allinen et al., 2004).
This analysis showed that MMP14 was highly expressed in
myoepithelial cells and myofibroblasts, and its expression in-
creased in DCIS-associated myoepithelial cells compared to
normal ones (data not shown). To confirm the SAGE data, we
analyzed the expression of MMP14 by real-time PCR in bulk
tumor samples as well as in purified epithelial and myoepithelial
cells, and myofibroblasts. Highest MMP14 expression was de-
tected in myofibroblasts and in DCIS-associated myoepithelium
(Figure 2E). High MMP14 levels in bulk invasive tumor tissue
were likely due to its expression in myofibroblasts since tumor
epithelial cells had low levels of MMP14. Next, we tested the
expression of MMP14 in MUC1+ and ITGB6+ cells isolated
from MCFDCIS xenografts. Correlating with human primary
tumor data, MMP14 was highly expressed in ITGB6+ myoepithe-
lial cells (Figure 2F) strengthening the similarity between our
model and human DCIS. The expression pattern of MMP14 in
human breast tissue and in xenografts was consistent with the
hypothesis that it may be involved in BM degradation and in
invasive progression. However, due to the effect of MMP14
on multiple growth factors (including TGFb) and other MMPs
(e.g., MMP9 and MMP2), the consequences of increased
MMP14 expression are not easy to predict and its mRNA levels
may not always correlate with protease activity (Labbe et al.,
2007).
The Effect of Coinjected Normal Myoepithelial Cells and
Various Fibroblasts on Tumor Growth and Progression
Following the verification that the MCFDCIS xenograft model
reproduces main aspects of human basal-like DCIS tumors,
we used this model to test the role of nonepithelial cells in tumor
progression. We injected MCFDCIS cells into nude mice alone or
together with normal primary cultured or immortalized myoepi-
thelial cells (HME), or primary cultured fibroblasts derived from
normal breast tissue (PBS), invasive breast carcinomas (PBTS),
Cancer Cell
Myoepithelial Control of Breast Tumor Progressionand rheumatoid arthritis (RASF). All xenografts were analyzed at
early (3 to 4 weeks) time points after injection in order to avoid
spontaneous progression to invasive tumors. HME statistically
significantly suppressed tumor weight, PBS had no measurable
effect, and PBTS and RASF increased tumor weight (Figure 3A).
Microscopic examination revealed dramatic differences in his-
tology among the different coinjection groups. MCFDCIS cells
alone or coinjected with normal myoepithelial cells formed
DCIS, whereas coinjection of any fibroblasts resulted in invasive
carcinomas (Figure 3B). The DCIS and invasive histology was
confirmed by the immunohistochemical analysis of myoepithelial
markers. Similar to primary human tumors, MMP14 was highly
expressed in bulk invasive xenografts (data not shown). Analysis
of the expression of MIB1 (Ki67) revealed increased proliferation
in invasive tumors (Figure 3B), correlating with their faster growth
rate (data not shown). iFISH analyses of xenografts revealed lack
of human fibroblasts in the stroma of the tumors (Figure S6).
Thus, despite their inability to persist long-term in immunodefi-
cient mice, coinjected fibroblasts exert a long-lasting effect on
tumor weight and histology. All of these experiments were per-
formed at least three times with essentially the same results
using myoepithelial cells and fibroblasts derived from multiple
independent patients.
To define whether the normal myoepithelial cells can over-
come the tumor promoting effects of fibroblasts, we also ana-
lyzed xenografts obtained from the coinjection of all three cell
types: MCFDCIS tumor cells, normal myoepithelial cells, and
fibroblasts. Interestingly, inclusion of normal myoepithelial cells
was able to reverse the tumor growth and progression-promot-
ing effects of all fibroblasts since tumors derived from triple
injections were smaller and had DCIS histology (Figures 3C
and 3D).
To exclude the possibility that the tumor growth and progres-
sion-promoting effects of coinjected human fibroblasts were due
to the preferential outgrowth of a subpopulation of MCFDCIS
cells with preexisting or acquired invasive properties, we iso-
lated tumor epithelial cells from xenografts formed from
MCFDCIS cells alone and from different coinjections and rein-
jected them (without adding any nonepithelial cells) into new
(naive) nude mice. All reinjected tumors had DCIS histology, sug-
gesting that the MCFDCIS epithelial cells were similar in all
tumors and that fibroblasts have to be present at the time of
injection to exert their progression-promoting effects (Figure 3E).
SNP array analysis of xenografts formed from MCFDCIS cells at
different time points (38 weeks) and from different coinjection
groups also demonstrated that acquisition of additional genetic
alterations in tumor epithelial cells is not necessary for progres-
sion to invasion (Figure S3C).
Signaling Network in MCFDCIS Cells
Our gene expression data of epithelial and myoepithelial cells
purified from MCFDCIS xenografts and human primary tissue
suggested the preferential activation of the TGFb1, Hh, cell ad-
hesion, and p63 pathways in ITGB6+ myoepithelial cells (Table
1; Figure 2A; Figure S5). Recent studies have demonstrated sig-
nificant crosstalk among these signaling pathways (Di Marcotul-
lio et al., 2007; Lauth and Toftgard, 2007). Thus, we investigated
the activity of these pathways and their role in regulating myoe-
pithelial cell phenotypes in MCFDCIS cells.To determine if TGFb1 influences cell adhesion or p63,
MCFDCIS cells grown in 2D or in suspension cultures were ana-
lyzed at different time points following TGFb1 treatment for the
expression of p63 and for targets of the two pathways. TGFb1
did not affect p63 in any conditions analyzed, but upregulated
the expression of integrin b6, laminin 5, and vimentin, whereas
p63 protein levels decreased in suspension (Figure 4A), consis-
tent with prior studies in MCF10A cells (Carroll et al., 2006).
Next, we analyzed the transcriptional activity of the TGFb and
Hh pathways in MCFDCIS cells using luciferase reporter con-
structs. As expected, strong TGFb transcriptional activation
was observed following TGFb1 treatment, which was eliminated
by treatment with a TGFBR1 inhibitor (Figure 4B). Treatment with
TGFb1 also increased Gli transcriptional activity and Gli2 protein
levels (Figures 4B and 4C). Unexpectedly, cyclopamine (an in-
hibitor of SMO activation) treatment alone increased the activity
of the TGFb responsive promoter, which was further augmented
by TGFb1 treatment (Figure 4B). The mechanism of this induc-
tion is unknown, but it appears to involve SMO and TGFb recep-
tors, since another SMO inhibitor had similar effects and
a TGFBR1 inhibitor abolished it (data not shown).
p63 has been shown to play an essential role in the regulation
of epithelial stem cell function and differentiation (McKeon,
2004). To determine the effect of constitutive overexpression
of p63 on TGFb and Hh signaling and luminal and myoepithelial
cell differentiation, we generated derivatives of MCFDCIS cells
overexpressing DNp63a (the predominant isoform in MCFDCIS
cells). Overexpression ofDNp63awas confirmed by immunoblot
analysis of its expression as well as that of its transcriptional
targets (Figure 4D). Control and DNp63a overexpressing cells
responded similarly to TGFb1 treatment, whereas the induction
of the Gli reporter by cyclopamine and cyclopamine+TGFb1
were more significant in DNp63a overexpressing than in control
cells presumably due to the induction of Gli2 expression by
DNp63a (Figures 4D and 4E). In summary, there appears to be
extensive crosstalk among the TGFb, Hh, cell adhesion, and
p63 signaling pathways in MCFDCIS cells (Figure 4F), and the
combined action of these pathways may be required for the
maintenance of the bipotential progenitor and differentiated
myoepithelial cell phenotypes.
Pathways Regulating Myoepithelial Differentiation
and Progression to Invasion
To determine if any of the pathways we identified as candidate
regulator of myoepithelial cell differentiation and progression to
invasion play an essential role in these processes, we generated
derivatives of MCFDCIS cells with altered expression of the
selected genes. Specifically, using lentiviral shRNA, we downre-
gulated SMAD4, TGFBR2, GLI2, and MMP14 levels (decreasing
p63 resulted in cell death), whereas using retroviral constructs,
we overexpressed DNp63a and MMP14 in MCFDCIS cells. For
each of the genes tested, 5–13 shRNAs were evaluated for effi-
cient downregulation of mRNA and the best two clones were fur-
ther validated for their effects on protein and signaling activity
(Figures S7 and S8). No significant phenotypic change was
observed in any of the MCFDCIS derivatives in culture (data
not shown).
Next, xenograft assays were performed to analyze gain-of-
function and loss-of-function effects on tumor weight andCancer Cell 13, 394–406, May 2008 ª2008 Elsevier Inc. 399
Table 1. Similarity of MUC1+ and ITGB6+ Cells to Epithelial and Myoepithelial Cells, Respectively, from Primary Human Tissue
Gene Description
Secreted protein,
acidic, cysteine-rich
Metallothionein 2A
Laminin, gamma 2
Transgelin
Tropomyosin 2 (beta)
Collagen, type IV, alpha 2
Myosin, light
polypeptide 9, regulatory
Translocase of outer
mitochondrial membrane
40 homolog
AXL receptor
tyrosine kinase
Nicotinamide
N-methyltransferase
Connective tissue
growth factor
SPARC-like 1
Collagen, type IV, alpha 1
Casein kinase 1, epsilon
Secreted protein,
acidic, cysteine-rich
Cyclin-dependent kinase
inhibitor 1A
Tropomyosin 1 (alpha)
Dual specificity
phosphatase 6
Keratin 5
Vimentin
Jumonji domain
containing 3
FXYD domain
containing ion transport
regulator 3
Neutrophil cytosolic
factor 1
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.ITGB6+ MUC1+
N-
MYOEP-
1
N-
MYOEP-
2
N-
MYOEP-
4
D-
MYOEP-
6
D-
MYOEP-
7
N-
EPI-
1
N-
EPI-
2
D-
EPI-
2
D-
EPI-
3
D-
EPI-
6
D-
EPI-
7
I-
EPI-
7
I-
EPI-
8
I-
EPI-
9
Unigene
ID No.
Gene
Symbol
Genes High in ITGB6+ and MYOEP
63 1 59 17 11 597 173 2 0 2 7 25 7 10 59 17 111779 SPARC
90 4 112 136 263 260 204 53 14 8 17 56 64 14 8 5 534330 MT2A
54 3 91 33 54 12 10 33 20 3 0 3 1 5 0 0 591484 LAMC2
24 1 114 45 149 36 58 0 6 5 0 8 4 3 15 3 632099 TAGLN
24 1 14 41 39 16 17 2 0 0 3 3 1 5 0 0 300772 TPM2
20 1 9 20 7 6 15 0 0 0 2 1 0 0 0 0 508716 COL4A2
13 0 45 31 13 26 38 2 2 6 3 5 3 5 8 20 504687 MYL9
121 13 7 48 26 91 56 4 2 3 16 4 2 7 23 5 110675 TOMM40
12 0 16 5 5 20 31 0 0 0 0 1 0 0 0 0 590970 AXL
12 1 23 42 17 59 60 18 0 0 9 5 2 3 11 0 503911 NNMT
23 3 58 53 28 106 162 0 0 8 21 10 7 4 17 23 591346 CTGF
9 0 26 39 18 96 37 0 6 2 3 8 7 7 8 2 62886 SPARCL1
8 0 12 6 0 31 17 0 2 0 0 5 0 0 0 0 17441 COL4A1
8 0 12 8 24 5 23 6 4 3 3 23 9 0 3 2 474833 CSNK1E
8 0 10 16 3 14 4 0 0 0 3 0 1 1 3 0 111779 SPARC
24 6 37 47 29 76 13 18 8 14 5 5 8 16 2 26 370771 CDKN1A
42 10 87 34 18 11 6 16 16 5 5 4 10 5 6 5 133892 TPM1
17 4 3 14 7 5 8 0 2 2 2 4 0 1 5 0 298654 DUSP6
82 22 66 122 159 44 29 16 26 5 3 4 1 1 3 2 433845 KRT5
107 37 38 36 101 102 121 4 8 3 10 15 6 7 20 15 533317 VIM
28 10 19 14 9 31 23 2 8 3 3 8 9 34 0 5 223678 JMJD3
Genes High in MUC1+ and EPI
47 99 2 23 11 7 4 39 53 139 14 22 76 33 56 21 301350 FXYD3
24 55 2 78 5 0 17 47 154 106 35 118 1090 347 51 120 520943 NCF1
16 37 3 5 4 2 0 2 12 14 17 0 9 7 5 5 346868 EBNA1BP2 EBNA1 binding protein 2
2 Synaptogyrin 2
SAM pointed
domain containing ets
transcription factor
Signal-transducing
adaptor protein-2
CD24 molecule
24 KIAA1324
D1 Tumor-associated
calcium signal
transducer 1
X-box binding
protein 1
2 Transmembrane 9
superfamily
member 2
2A2 Secretoglobin, family 2A,
member 2
Mal, T-cell differentiation
protein 2
4220 Similar to common
salivary protein 1
P1 Nerve growth
factor receptor
associated
protein 1
Biglycan
X Thymosin, beta 4,
X-linked
Mannose receptor,
C type 2
Complement
component 3
Latent transforming
growth factor beta
binding protein 3
ription are listed. N, normal; D, DCIS;
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n11 32 3 22 12 2 0 31 26 88 7 19 43 16 12 8 464210 SYNGR
7 21 0 2 0 0 0 2 6 36 0 12 15 5 21 5 485158 SPDEF
7 21 0 9 5 0 0 33 10 18 5 7 10 16 3 9 194385 STAP2
13 59 0 42 4 1 2 62 168 228 5 167 105 68 11 174 375108 CD24
0 7 0 5 0 0 0 4 6 12 2 10 19 7 14 3 642705 KIAA13
0 9 2 5 5 0 4 6 18 11 7 16 19 1 3 11 542050 TACST
0 9 37 20 14 16 10 88 51 207 33 30 109 68 47 27 437638 XBP1
1 10 5 2 0 1 4 6 18 8 2 4 10 4 11 18 130413 TM9SF
30 275 0 2 1 0 0 12 14 23 17 1 1 3 60 8 46452 SCGB
0 21 3 3 4 2 0 10 6 27 5 15 15 10 6 14 201083 MAL2
1 61 0 2 0 0 0 8 4 2 2 3 6 10 12 2 105887 LOC12
Genes High in ITGB6+ and DCIS-Associated MYOEP
15 1 5 8 5 55 77 14 22 45 0 11 4 3 3 12 448588 NGFRA
13 0 0 2 0 15 48 0 0 0 2 4 0 0 0 0 821 BGN
9 0 3 5 1 45 58 2 2 6 9 29 8 15 8 20 522584 TMSB4
40 9 2 2 1 21 19 0 0 2 5 1 0 0 6 0 7835 MRC2
17 4 0 6 3 69 27 0 4 0 0 4 3 4 8 5 529053 C3
42 13 0 5 4 20 79 6 0 6 2 7 22 8 5 18 289019 LTBP3
Detailed description of SAGE libraries and their analysis are included in the Supplemental Data. Normalized tag counts, Unigene ID, gene symbol, and gene desc
I, invasive ductal carcinoma. Genes related to TGFb1 signaling are italicized.
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Myoepithelial Control of Breast Tumor Progressionhistology. Downregulation of TGFBR2 and SMAD4 increased
tumor weight and promoted invasive histology due to a decrease
in myoepithelial cells (Figures 5A and 5B). Downregulation of Gli2
similarly promoted progression to invasion, but decreased tumor
weight (Figures 5C and 5D). Thus, the invasive tumor phenotype
was independent of tumor size but was determined by the pres-
ence of myoepithelial cells. Overexpression of MMP14 did not
have significant effect on MCFDCIS xenografts (Figures S8A
and S8B; data not shown). In contrast, xenografts derived from
MCFDCIS cells expressing MMP14 shRNA showed loss of
myoepithelial cells and invasive phenotype, but had no differ-
ence in tumor weight compared to shGFP controls (Figures
S8C–S8D; data not shown). Overexpression of DNp63a had no
effect on MCFDCIS xenografts (Figure S8E; data not shown).
DISCUSSION
The DCIS to invasive carcinoma transition is a clinically important
yet poorly understood step of breast tumorigenesis (Allred et al.,
2001; Burstein et al., 2004). Others and we have analyzed the
gene expression and genetic profiles of tumor epithelial cells iso-
lated from DCIS and invasive tumors but have not been able to
define a tumor stage-specific molecular event (Chin et al.,
2004; Ma et al., 2003; Porter et al., 2003; Yao et al., 2006). At
the same time, the importance of changes in the microenviron-
Figure 3. The Effect of Nonepithelial Cells
on MCFDCIS Xenografts
(A) The effect of coinjection of different cells on
tumor weight. Normal myoepithelial cells (HME)
significantly suppressed tumor weight, fibroblasts
from normal breast (PBS) had no effect, and fibro-
blasts from breast tumors (PBTS) and rheumatoid
arthritis synovium (RASF) increased tumor weight.
(B) Histological and immunohistochemical analy-
ses of MCFDCIS xenografts from coinjection
experiments.
(C and D) The dominant effect of normal myoepi-
thelial cells on tumor weight (C) and histology (D).
Tumors resulting from the injection of MCFDCIS
cells together with PBS+HME, PBTS+HME, and
RASF+HME were significantly smaller and had
DCIS histology compared to xenografts initiated
from MCFDCIS cells coinjected with fibroblasts
(PBS, PBTS, or RASF).
(E) Tumors of various coinjections were removed
and analyzed 22 days after injection (original day
22). Reinjection of MCFDCIS cells isolated from
these tumors (without any coinjection) resulted in
DCIS-like xenografts (reinjected day 22).
Scale bars correspond to 100 mm in all panels.
ment during tumor progression has been
increasingly recognized (Bissell et al.,
2005; Tlsty and Hein, 2001; Weinberg
and Mihich, 2006). Focal disruption of
basement membrane appears to coin-
cide with the disappearance of myoepi-
thelial cells and stromal changes in hu-
man DCIS with high risk of progression
to invasive carcinoma (Man et al., 2003). Correlating with the dis-
appearance of the myoepithelial cells during the in situ to inva-
sive carcinoma transition, the gene expression and epigenetic
profiles of myoepithelial cells associated with DCIS become dis-
tinct from those in normal breast (Allinen et al., 2004; Hu et al.,
2005). The signals that initiate these changes are unknown, al-
though paracrine interactions with neoplastic epithelial and a va-
riety of stromal cells are potential candidates. In contrast to nor-
mal myoepithelial cells, tumor-associated fibroblasts and
myofibroblasts have been shown to promote tumorigenesis (Bis-
sell et al., 2005; Tlsty and Hein, 2001; Weinberg and Mihich,
2006). We therefore tested the hypothesis that myoepithelial
cells and fibroblasts regulate the in situ to invasive carcinoma
transition using a xenograft model of human DCIS and primary
human breast tumors.
The MCFDCIS cells form DCIS-like xenografts that spontane-
ously progress to invasive carcinomas. Based on our molecular
analyses, this xenograft model resembles human basal-like
DCIS. We demonstrated that in the absence of normal myoepi-
thelial cells, coinjection of fibroblasts (regardless of their tissue
of origin) promoted progression of DCIS to invasive tumors.
Additionally, breast tumor-associated and, even more dramati-
cally, inflammatory fibroblasts from rheumatoid arthritis, also
increased tumor growth. Coinjection of normal myoepithelial
cells overcame the tumor progression-promoting effects of402 Cancer Cell 13, 394–406, May 2008 ª2008 Elsevier Inc.
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Myoepithelial Control of Breast Tumor ProgressionFigure 4. Pathways Regulating Myoepithelial Cell Phenotypes
(A) Immunoblot analysis of MCFDCIS cells treated with TGFb1 for the indicated time in attached or suspension culture. Integrin b6, laminin 5, and vimentin levels
are increased following TGFb1 treatment. p63 is not affected by TGFb1, but it is downregulated in suspension.
(B) TGFb and Hh pathway activity in MCFDCIS cells following the indicated treatments determined using luciferase reporters. Error bars represent mean ± SD.
(C) Immunoblot analysis of Gli2 protein levels in MCFDCIS cells treated with TGFb1 for the indicated time in attached culture.
(D) Immunoblot analysis of MCFDCIS cells infected with control (pBabe) andDNp63a overexpressing retroviruses. DNp63a overexpression increases integrin b6,
laminin 5, vimentin, and Gli2 levels.
(E) TGFb and Hh pathway activity in control andDNp63a overexpressing MCFDCIS cells following the indicated treatments determined using luciferase reporters.
Error bars represent mean ± SD.
(F) Summary of interactions among TGFb, Hh, cell adhesion, and p63 pathways.fibroblasts and effectively suppressed tumor weight. Most im-
portantly, these differences in tumor growth and histology
were not caused by permanent genetic changes in the epithelial
cells of the tumors. Furthermore, MCFDCIS cells retrieved from
invasive tumors were still able to form DCIS when reinjected
into naive mice in the absence of additional fibroblasts.
We found that the unique ability of the MCFDCIS cells to form
DCIS is due to their bipotential progenitor property that enables
their differentiation into luminal and myoepithelial cells in vivo.
Differentiation to the myoepithelial cell phenotype is required
for DCIS histology. Based on our data, we hypothesized that
this process is influenced by coinjected normal myoepithelial
cells and fibroblasts, presumably via paracrine factors.
Based on our immunohistochemical analyses and gene
expression profiling of luminal and myoepithelial cells isolated
from DCIS xenografts and human breast tissue, we identified
TGFb, Hh, cell adhesion, and p63 signaling pathways as potential
regulators of the luminal and myoepithelial cell phenotypes. We
found extensive crosstalk among these pathways in MCFDCIS
cells and demonstrated that decreasing TGFb and Hh pathway
activity via downregulating TGFBR2/SMAD4 and Gli2 expression,
respectively, resulted in the loss of myoepithelial cells and accel-erated progression to invasion. These findings suggest a critical
role for TGFb and Hh signaling in breast tumor progression.
Many of the targets of these signaling pathways encode ECM
proteins and receptors, and several of these are regulated by
more than one signaling pathway. For example, both p63 and
TGFb1 upregulate ITGB6 expression, which in turn can activate
latent TGFb1, generating a positive feedback loop. At the same
time, p63 protein levels are regulated by cell adhesion, and
luminal epithelial differentiation may be initiated by detachment
from basement membrane (BM) and subsequent downregula-
tion of p63.
Gene ontology analysis of genes differentially expressed be-
tween epithelial and myoepithelial cells isolated from primary hu-
man tissue as well as from MCFDCIS xenografts demonstrated
that myoepithelial cells play important roles in BM synthesis and
maintenance. The phenotypic changes that occur in these cells
in DCIS may lead to progressive degradation of BM, which elim-
inates the barrier between the epithelial and stromal cell compart-
ments and also results in the loss of myoepithelial cells. Thus, the
integrity of BM may be key to the maintenance of the basal/myo-
epithelial cell layer. Proteases secreted by tumor epithelial and
other cells in the microenvironment may promote tumorCancer Cell 13, 394–406, May 2008 ª2008 Elsevier Inc. 403
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Myoepithelial Control of Breast Tumor Progressionprogression viadestroying the BM, resulting in the loss of bipoten-
tial progenitors and myoepithelial cells. Consistent with these, we
found dramatic upregulation of MMP14 in DCIS-associated myo-
epithelial cells of human tissue and in the ITGB6+ myoepithelial
cells of MCFDCIS xenografts. However, when we tested the
effect of MMP14 downregulation in the MCFDCIS model, we
found that decreased MMP14 levels led to decreased number
of myoepithelial cells and invasive histology. This seemingly
paradoxical effect is likely due to the intricate interactions be-
tween TGFb and MMP14. Specifically, MMP14 activates TGFb
by releasing it from its latent form, and TGFb upregulates
MMP14 (Labbe et al., 2007; Mu et al., 2002). Therefore, modulat-
ing MMP14 expression influences TGFb signaling, which we
showed was required for the myoepithelial cell phenotype.
Thus, the effects of MMP14 overexpression or loss are context
dependent.
Human DCIS has been shown to have numerous genetic alter-
ations and is almost indistinguishable from invasive tumors (Chin
et al., 2004; Yao et al., 2006). As such, additional mutations in the
epithelial cells are not necessary for the in situ to invasive transi-
tion; loss of the BM, epithelial cell organization and polarity due
to disappearance of myoepithelial cells, appears to be sufficient
Figure 5. Pathways Regulating In Situ to Invasive
Carcinoma Progression
(A and B) The effect of loss of TGFb signaling in MCFDCIS
cells on tumor weight (A) and histology (B). Downregulation
of TGFBR2 (in one of the clones) or SMAD4 increased
tumor weight (TGFBR2-A3, p = 0.7899; TGFBR2-B1,
p = 0.02996; SMAD4-C9, p = 0.09847; SMAD4-D1,
p = 0.2379) and resulted in invasive tumors.
(C and D) The effect of decreased Gli2 expression in
MCFDCIS cells on tumor weight (C) and histology (D).
Downregulation of Gli2 decreased tumor weight
(GLI2-A6, p = 0.1605; GLI2-A8, p = 0.2786), but
increased invasive histology. Scale bars correspond to
100 mm in all panels.
(E) Hypothetical model summarizing our results and ex-
plaining in situ to invasive breast carcinoma progression.
Bipotential mammary epithelial progenitor cells can give
rise to myoepithelial and luminal cells. Detachment from
the basement membrane (BM) and subsequent downregu-
lation of TGFb, Hh, integrin-ECM, and p63 pathways lead
to luminal epithelial differentiation. Myoepithelial cells are
necessary for the formation of DCIS. Stromal fibroblasts
promote while normal myoepithelial cells inhibit tumor
progression in part through their effects on the BM.
to pave the way for tumor progression and inva-
sion. A simplified view of these dynamic cellular
and signaling interactions and their effect on the
DCIS to invasive carcinoma progression are
summarized in Figure 5E. Breast tumors are
very heterogeneous with several distinct molec-
ular subtypes and potentially distinct tumor pro-
gression pathways. MCFDCIS cells resemble
basal-like breast tumors thought to originate
from bipotential stem cells (Yehiely et al.,
2006). Specifically, the ITGB6+ myoepithelial
cells are derived from MCFDCIS cells; thus,
they are genetically abnormal contrary to myoepithelial cells iso-
lated from human nonbasal DCIS (Allinen et al., 2004). However,
due to the fact that DCIS extends into normal ducts and lobules,
genetically abnormal myoepithelial cells may only be detectable
at the site of tumor initiation. Indeed, our careful examination of
slides dual stained for p53 and CK5 from basal-like DCIS identi-
fied rare double-positive cells potentially reflecting myoepithelial
cells with mutant p53. Further molecular analysis of these cells in
multiple DCIS tumors is necessary to confirm the presence of ge-
netically abnormal myoepithelial cells and to determine if this in-
fluences risk of progression to invasion. However, our model
may not be universally true for all breast tumors, and there are
possibly other pathways of progression to invasive breast carci-
noma.
In summary, our data suggest that the progression of in situ to
invasive breast carcinoma may not be due to the intrinsic proper-
ties of the tumor epithelial cells acquired during tumor evolution
but determined by complex interactions among all the cell types
that compose the tumor microenvironment. Our conclusions are
based the characterization of a xenograft model of human DCIS
and primary human breast tissue samples. Thus, our results not
only highlight the importance of the microenvironment in breast404 Cancer Cell 13, 394–406, May 2008 ª2008 Elsevier Inc.
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Myoepithelial Control of Breast Tumor Progressiontumor progression, but also point to the significance of the myo-
epithelial cell layer and basement membrane as gatekeepers
of DCIS. Furthermore, the results suggest that therapeutic strat-
egies targeting interactions of tumor epithelial cells with their
surroundings may be more beneficial to inhibiting tumor progres-
sion than focusing on the tumor epithelial cells alone.
EXPERIMENTAL PROCEDURES
Cells and Tissue Specimens
MCF10A-series was obtained from Dr. Fred Miller (Karmanos Cancer Institute,
Detroit, MI). HME50 and D920 immortalized myoepithelial cells (Gudjonsson
et al., 2002a; Shay et al., 1995) were generously provided by Drs. Jerry Shay
and Ole Petersen. RASF were generous gifts by Drs. Steve Goldring and
John D. Mountz. Primary normal myoepithelial cells and fibroblasts from nor-
mal and neoplastic breast were purified from tissue samples from the Brigham
and Women’s Hospital (Boston, MA) as previously described (Allinen et al.,
2004). All human tissue was collected using protocols approved by the Institu-
tional Review Boards. Cells were grown in the media recommended by the
providers. Myoepithelial cells were maintained in MEGM (Cambrex, Walkers-
ville, MD), while fibroblasts were kept in DMEM (Invitrogen, Carlsbad, CA) with
10% iron fortified bovine calf serum (Hyclone, Logan, UT). Generation of retro-
viruses and lentiviruses and infection of MCFDCIS cells were carried out as
previously described (Carroll et al., 2006; Moffat et al., 2006).
Xenograft Experiments
For xenograft studies 100,000 MCFDCIS cells were injected subcutaneously
into 6- to 9-week-old female nude mice alone or together with 2- to 3-fold
excess of HME, RASF, PBS, or PBTS cells in 50% Matrigel (BD Biosciences,
Bedford, MA). Tumors were allowed to grow for 3–8 weeks. Xenografts were
weighed and then either snap frozen on dry ice and stored at 80C for
DNA/RNA purification, formalin fixed and paraffin embedded, or processed
for cell sorting. Animal experiments were conducted following protocols
approved by the Harvard Medical School Animal Care and Use Committee.
Immunohistochemistry, Immunocytochemistry,
Immunofluorescence, Immunoblot, iFISH, and FACS Analyses
The list of antibodies used is provided in Table S2. Immunoblot, immunocyto-
chemistry, and FACS analyses were performed as recommended by the
suppliers essentially as previously described (Allinen et al., 2004). Immunohis-
tochemistry and iFISH procedure are described in the Supplemental Data.
Cell Purification, SAGE, SNP Array, PCR, and Statistical Analyses
Cell purification and SAGE library generation and analyses were performed as
described previously (Allinen et al., 2004), except that MUC1 (clone DF3) and
ITGB6 (clone 3G9) antibodies were used. Gene ontology enrichment and clus-
tering analyses are described in the Supplemental Data. SNP array analysis
was performed by the Dana-Farber Microarray Core using Affymetrix 11K
XbaI or 250K StyI SNP arrays as described (Allinen et al., 2004). cDNA synthe-
sis, quantitative RT-PCR, and semiquantitative RT-PCR were carried out as de-
scribed (Allinen et al., 2004; Hu et al., 2005). A list of primers used is available
upon request. Xenograft weights and relative gene expression levels were an-
alyzed using two-sided exact Wilcoxon Rank Sum test stratified by experiment
when the data from different experiments were combined. In mouse xenograft
experiments when both sides of the mouse got the same injection and the
weights of the two tumors correlated, the average of the two tumor weights
was used as the end point. There were no corrections for multiple comparisons.
Luciferase Assays
Cells were transfected with TGFb (p3TP-lux) or Gli (pGL3B-8XGliBS-lc-luc)
reporter constructs (Cooper et al., 2003; Sasaki et al., 1997; Wrana et al.,
1992) together with renilla luciferase. Twenty-four hours posttransfection, cells
were treated and incubated for another 24 hr, and then luciferase activity was
determined. For cells treated in suspension, transfection was performed in
attached culture, and then cells were split into ultra-low-binding 24-well plates
and treated.ACCESSION NUMBERS
SAGE and SNP data were deposited to the Cancer Genome Anatomy Project
(http://cgap.nci.nih.gov/SAGE) and to the Gene Expression Omnibus (http://
www.ncbi.nlm.nih.gov/projects/geo; accession no. GSE10747), respectively.
SUPPLEMENTAL DATA
The Supplemental Data include Supplemental Experimental Procedures, five
supplemental tables, and eight supplemental figures and can be found with
this article online at http://www.cancercell.org/cgi/content/full/13/5/394/
DC1/.
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